Submit Article
Legal Analysis. Regulatory Intelligence. Jurisprudence.
Singapore

MERCK SHARP & DOHME CORP. v MERCK KGaA

In MERCK SHARP & DOHME CORP. v MERCK KGaA, the Court of Appeal of the Republic of Singapore addressed issues of .

Case Details

  • Citation: [2021] SGCA 14
  • Court: Court of Appeal of the Republic of Singapore
  • Date of Decision: 26 February 2021
  • Case Title: Merck Sharp & Dohme Corp v Merck KGaA
  • Civil Appeal No: 223 of 2019
  • Related Suit: Suit No 415 of 2018 (Summons No 4434 of 2018)
  • Judges: Sundaresh Menon CJ, Andrew Phang Boon Leong JCA, Judith Prakash JCA, Steven Chong JCA, Quentin Loh JAD
  • Plaintiff/Applicant: Merck Sharp & Dohme Corp (formerly known as Merck & Co, Inc)
  • Defendant/Respondent: Merck KGaA (formerly known as E Merck)
  • Procedural Posture (as reflected in the extract): Appeal concerning whether issue estoppel and/or abuse of process applied in Singapore proceedings, in light of prior foreign judgments
  • Legal Areas: Civil procedure; res judicata; issue estoppel; abuse of process; conflict of laws; recognition/enforcement of foreign judgments (contextual)
  • Statutes Referenced: Choice of Court Agreements Act (Cap 39A, 2017 Rev Ed) (CCAA); Reciprocal Enforcement of Commonwealth Judgments Act (Cap 264, 1985 Rev Ed) (REFCJA) (noted as slated for repeal); Reciprocal Enforcement of Foreign Judgments Act (Cap 265, 2001 Rev Ed) (REFJA) (noted as amended)
  • Cases Cited (as provided): [2019] SGHC 231; [2021] SGCA 14
  • Other Key Foreign/Related Decisions Mentioned: Merck KGaA v Merck Sharp & Dohme Corp & Others [2014] EWHC 3867 (Ch); Merck KGaA v Merck Sharp & Dohme Corp, Merck & Co Inc, Merck Sharp & Dohme Limited, Intervet UK Limited, Intervet International BV [2016] EWHC 49 (Pat); Merck KGaA v Merck Sharp & Dohme Corp, Merck & Co, Inc, Merck Sharp & Dohme Ltd, Intervet UK Ltd, Invervet International BV [2017] EWCA Civ 1834; Merck KGaA v Merck Sharp & Dohme Corp (and others) [2020] EWHC 1273 (Ch); Merck KGaA v Merck Sharp Dohme Corp [2019] FCA 1084
  • Judgment Length: 45 pages; 14,179 words

Summary

In Merck Sharp & Dohme Corp v Merck KGaA ([2021] SGCA 14), the Court of Appeal addressed when issue estoppel and related abuse-of-process doctrines should apply in Singapore where the alleged estoppel is said to arise from prior foreign litigation. The dispute arose from a long-running global “Merck” branding and naming arrangement between two corporate branches of the Merck family business, governed by a 1970 Agreement and a 1975 Letter. After extensive proceedings in England and elsewhere, the parties commenced proceedings in Singapore concerning trade mark infringement, passing off, and breach of contract.

The Court of Appeal emphasised that while domestic issue estoppel is animated by two core rationales—protecting defendants from unfair vexation and upholding the finality of litigation—transnational issue estoppel requires additional considerations because it implicates Singapore’s international relations and the broader legal architecture for cross-border recognition and enforcement of judgments. The Court held that the principles governing domestic issue estoppel (as articulated in RBS v TT International) cannot be applied mechanically to transnational issue estoppel; instead, they must be recalibrated to serve the interests of justice in a cross-border context.

What Were the Facts of This Case?

The parties trace their origins to a German family business that began in 1668 under the name “E Merck”. Over time, the business developed separately in Europe and North America. In the 1970s, the predecessors of Merck Sharp & Dohme Corp (the “Appellant”) and Merck KGaA (the “Respondent”) entered into a co-existence arrangement to govern how the “Merck” name could be used across different jurisdictions. The arrangement was documented in two instruments: a “1970 Agreement” and a “1975 Letter”.

The 1970 Agreement allocated rights and restrictions by geography. In broad terms, it recognised an exclusive right of Merck & Co. (the Appellant’s predecessor) to use the “Merck” trademark in the United States and Canada, while recognising the Respondent’s exclusive right to use “Merck” in Germany. For “all other countries”, the agreement provided that “Merck Sharp & Dohme” could be used as a trademark or name without being confusingly similar to the Respondent’s marks, and that the Respondent would not object to the Appellant’s use and registration of “Merck Sharp & Dohme” in those jurisdictions. The agreement also contained provisions restricting the Appellant’s ability to use “Merck” on its own as a firm name or corporate name in the “rest of the world” (as later interpreted by the English courts).

As is typical in disputes involving global branding, the parties became embroiled in litigation across multiple jurisdictions. The extract highlights proceedings in the United States, England, Germany, Switzerland, Mexico, India, Australia, China, and Hong Kong. For Singapore’s purposes, the most relevant decisions were three English decisions delivered before the Singapore proceedings began: (a) an English High Court preliminary determination that the governing law of the 1970 Agreement and 1975 Letter was German law; (b) a High Court decision interpreting the agreement (including clause 7) and holding that the agreement precluded the Appellant from using “Merck” on its own in “the rest of the world” and that the Appellant breached the agreement; and (c) the English Court of Appeal decision affirming the High Court’s interpretation.

After the English Court of Appeal decision, some issues were remitted to the High Court, producing a further decision in 2020. However, the Court of Appeal in Singapore indicated that this later decision was not relevant to the particular issues in the Singapore appeal. The Appellant also relied on an Australian Federal Court decision in 2019, where the court declined to decide separately whether the English Court of Appeal decision gave rise to issue estoppel in respect of clause 7, partly because the substantive proceedings were later settled by consent without admissions.

The central legal issues concerned whether the doctrines of res judicata—particularly issue estoppel and cause of action estoppel—should prevent the parties from litigating matters in Singapore that had already been decided in foreign proceedings. The Court of Appeal also had to consider the related doctrine of abuse of process, including whether a party’s attempt to litigate in Singapore was inconsistent with positions taken in earlier proceedings.

Crucially, the Court had to distinguish between “domestic issue estoppel” (where the prior decision is a local Singapore decision) and “transnational issue estoppel” (where the prior decision is a foreign judgment). The Court of Appeal recognised that while the same overarching objectives—preventing double vexation and upholding finality—underpin both, the transnational setting introduces additional interests of justice and international comity concerns. The Court therefore needed to determine how the legal rules for issue estoppel should be adapted when the prior judgment is foreign.

Finally, the Court’s analysis was framed against the backdrop of Singapore’s evolving legislative approach to cross-border dispute resolution. The Court referenced the Choice of Court Agreements Act (CCAA) and noted the planned repeal of the Reciprocal Enforcement of Commonwealth Judgments Act, as well as amendments to the Reciprocal Enforcement of Foreign Judgments Act (REFJA). These developments were relevant to how Singapore should calibrate its approach to foreign judgments and the finality they should be accorded.

How Did the Court Analyse the Issues?

The Court of Appeal began by situating issue estoppel, cause of action estoppel, and abuse of process within the “armoury” of doctrines designed to ensure that litigants are not twice vexed over the same or sufficiently similar issues, while also promoting finality. It then identified the two principal rationales that animate domestic issue estoppel: (1) protecting defendants from unfair vexation and (2) upholding the public interest in finality of litigation. These rationales guide the formulation of the applicable legal rules in domestic settings.

However, the Court stressed that transnational issue estoppel is not simply a domestic issue estoppel problem with a foreign label. When the prior decision is foreign, additional considerations arise. The Court of Appeal explained that the application of issue estoppel in Singapore based on foreign judgments can affect Singapore’s international relations. In other words, Singapore’s willingness to treat foreign judgments as preclusive must be consistent with its broader approach to cross-border legal cooperation and the expectations of foreign courts and litigants.

To address this, the Court held that the principles governing domestic issue estoppel, as set out in The Royal Bank of Scotland NV v TT International Ltd and others [2015] 5 SLR 1104 (“RBS”), cannot apply without modification to transnational issue estoppel. The Court characterised the need for “modification” as especially important where the application of the relevant principles might impact Singapore’s international relations. This is a significant doctrinal move: it signals that the preclusive effect of foreign judgments is not governed by an identical template to domestic judgments.

In recalibrating the approach, the Court also considered legislative developments. The Court referenced the CCAA, the slated repeal of the REFCJA, and amendments to the REFJA. While the extract does not set out the full legislative reasoning, the Court’s point was that Singapore’s statutory framework for cross-border dispute resolution and judgment recognition/enforcement reflects a policy direction. That policy direction should inform how courts decide whether and when to give foreign judgments issue-preclusive effect in Singapore. The Court therefore treated the legislative landscape as a relevant contextual factor in shaping the “interests of justice” analysis for transnational issue estoppel.

On the abuse-of-process dimension, the Court also considered whether inconsistent positions had been taken by a party across proceedings. Abuse of process is a flexible doctrine, but it is not a substitute for res judicata. The Court’s framing suggests that abuse of process may be engaged where a litigant’s conduct undermines the integrity of the judicial process, including where it attempts to relitigate matters in a manner inconsistent with earlier determinations. In a transnational setting, however, the Court’s emphasis on international comity and the interests of justice indicates that abuse-of-process findings must be approached with care so as not to overreach beyond what finality and fairness require.

What Was the Outcome?

The Court of Appeal’s decision, as reflected in the extract, proceeded on the basis that the legal principles for domestic issue estoppel require modification when dealing with transnational issue estoppel. The Court’s approach therefore recalibrated the framework for determining whether the foreign English decisions should preclude further litigation in Singapore.

Practically, the outcome is that Singapore courts must undertake a more nuanced, context-sensitive analysis before applying issue estoppel based on foreign judgments. The Court’s guidance is directed at ensuring that the doctrines of finality and fairness operate in a way that is consistent with Singapore’s international relations and legislative policy on cross-border dispute resolution.

Why Does This Case Matter?

Merck Sharp & Dohme Corp v Merck KGaA is important because it clarifies that issue estoppel is not a one-size-fits-all doctrine. By distinguishing domestic and transnational issue estoppel and requiring modification of the domestic framework, the Court of Appeal provided a principled basis for Singapore courts to decide when foreign judgments should have preclusive effect. This is particularly relevant in commercial disputes where parties litigate in multiple jurisdictions and seek to use earlier foreign determinations to narrow or terminate subsequent proceedings.

For practitioners, the case offers a structured way to argue and assess preclusion. It highlights that the “interests of justice” analysis in transnational settings must account for fairness to the defendant, finality, and also the broader implications for Singapore’s international relations. Lawyers should therefore expect courts to scrutinise not only whether the elements of issue estoppel appear to be satisfied, but also whether applying them would be consistent with Singapore’s cross-border policy posture.

The case also has practical implications for litigation strategy. Parties cannot assume that an English (or other foreign) appellate decision automatically closes the door in Singapore. Conversely, a party seeking to resist relitigation cannot rely solely on the fact that the earlier decision was foreign. Instead, the court will engage in a calibrated analysis that balances finality and fairness with international comity and legislative context.

Legislation Referenced

  • Choice of Court Agreements Act (Cap 39A, 2017 Rev Ed) (“CCAA”)
  • Reciprocal Enforcement of Commonwealth Judgments Act (Cap 264, 1985 Rev Ed) (“REFCJA”) (noted as slated for repeal)
  • Reciprocal Enforcement of Foreign Judgments Act (Cap 265, 2001 Rev Ed) (“REFJA”) (noted as amended)

Cases Cited

  • [2015] 5 SLR 1104 — The Royal Bank of Scotland NV (formerly known as ABN Amro Bank NV) and others v TT International Ltd (nTan Corporate Advisory Pte Ltd and others, other parties) and another appeal
  • [2019] SGHC 231
  • [2021] SGCA 14 — Merck Sharp & Dohme Corp v Merck KGaA
  • [2014] EWHC 3867 (Ch) — Merck KGaA v Merck Sharp & Dohme Corp & Others
  • [2016] EWHC 49 (Pat) — Merck KGaA v Merck Sharp & Dohme Corp, Merck & Co Inc, Merck Sharp & Dohme Limited, Intervet UK Limited, Intervet International BV
  • [2017] EWCA Civ 1834 — Merck KGaA v Merck Sharp & Dohme Corp, Merck & Co, Inc, Merck Sharp & Dohme Ltd, Intervet UK Ltd, Invervet International BV
  • [2020] EWHC 1273 (Ch) — Merck KGaA v Merck Sharp & Dohme Corp, Merck & Co Inc, Merck Sharp & Dohme Limited, Intervet UK Limited, Intervet International BV
  • [2019] FCA 1084 — Merck KGaA v Merck Sharp Dohme Corp

Source Documents

This article analyses [2021] SGCA 14 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.

Written by Sushant Shukla

More in

Legal Wires

Legal Wires

Stay ahead of the legal curve. Get expert analysis and regulatory updates natively delivered to your inbox.

Success! Please check your inbox and click the link to confirm your subscription.